A Review of Small Molecules and Their Therapeutic Targets

Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation (ASCT), has changed dramatically in the past 20 years as three new classes of small molecule drugs (arbitrarily defined as having molecular weights of less than 900 kDa) - immunomodulators (IMiDs), proteasome inhibitors (PIs), and histone deacetylase (HDAC) blockers - have been introduced for the disease. Therapeutic options for MM expanded further in 2015 when two new monoclonal antibodies (daratumumab and elotuzumab) were approved by the FDA for MM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research